<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63902">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02084537</url>
  </required_header>
  <id_info>
    <org_study_id>577235</org_study_id>
    <nct_id>NCT02084537</nct_id>
  </id_info>
  <brief_title>Minimally Invasive Surgery vs. Endoscopy Randomized (MISER) Trial for Symptomatic Walled-Off Pancreatic Necrosis</brief_title>
  <acronym>MISER</acronym>
  <official_title>Minimally Invasive Surgeryvs. Endoscopy Randomized (MISER) Trial for Symptomatic Walled-Off Pancreatic Necrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Florida Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Florida Hospital</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multi-center randomized controlled trial comparing EUS-Guided cystgastrostomy
      or cystduodenostomy and endoscopic necrosectomy to minimally invasive surgical necrosectomy,
      in patients with symptomatic or infected WOPN.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomly allocated to either treatment arm in a 1:1 ratio.  Following
      intervention, patients will be assessed at regular intervals intil study completion at 6
      months post-discharge. Primary outcome is a composite of major complications or mortality,
      measured to 3 months post-discharge.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Major complications</measure>
    <time_frame>3 months post discharge</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Composite of major complications and mortality (all cause and disease specific), measured to 3 months post discharge</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Walled Off Pancreatic Necrosis</condition>
  <arm_group>
    <arm_group_label>Endoscopic treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treated by single transmural cystastrostomy, 12mm balloon dilation (10mm if cystuodenostomy), two 7Fr double pigtail plastic stents and nasocystic drainage catheter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minimally invasive surgical necrosectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First line approach is video assisted retroperitoneal debridement (VARD), or transperitoneal tract debridement.  If this is not possible due to the location of the collection, second line approach is a laproscopic approach.  This includes transperitoneal laproscopy, cystgastrostomy, or transgastric cystgastrostomy with internal debridement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic treatment</intervention_name>
    <description>Treated by single transmural cystgastrostomy, 12mm balloon dilation (10mm if cystduodenostomy), two 7fr double pigtail plastic stents and nasocystic drainage catheter.</description>
    <arm_group_label>Endoscopic treatment</arm_group_label>
    <other_name>Endoscopic cystgastrostomy</other_name>
    <other_name>Endoscopic cystduodenostomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Minimally invasive surgical necrosectomy</intervention_name>
    <description>First line approach is video assisted retroperitoneal debridement (VARD), or transperitoneal tract debridement.
If this is not possible due to the location of the collection, second line approach is a laparoscopic approach. This includes transperitoneal laparoscopy cystgastrostomy, or transgastric cystgastrostomy with internal debridement.  If percutaneous tract access and debridement is planned, surgery is to be performed no later than 48 hours after interventional radiology insert percutaneous drain.</description>
    <arm_group_label>Minimally invasive surgical necrosectomy</arm_group_label>
    <other_name>video assisted retroperitoneal debridement (VARD)</other_name>
    <other_name>transperitoneal tract debridement</other_name>
    <other_name>laparoscopic approach</other_name>
    <other_name>transperitoneal laparoscopy cystgastrostomy</other_name>
    <other_name>transgastric cystgastrostomy with internal debridement</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Walled off pancreatic necrosis

               -  Symptomatic: Pain, gastric outlet, intestinal or biliary obstruction, new-onset
                  or persisting organ failure, or 'persisting unwellness'.

               -  Infected (suspected and confirmed): clinical signs of infection (septic,
                  positive blood cultures, febrile), systemic inflammatory response syndrome, gas
                  within the collection on imaging (not iatrogenic), or positive culture of
                  collection contents

          -  Necrotic collection has developed a wall, typically around 4 weeks post presentation,
             and is within 15mm of the lumen of the gastrointestinal tract.

          -  Informed consent obtained from the patient or their medical representative.

             -&gt; 18 years old

          -  Medically fit for general anesthetic

          -  Collection amenable to either endoscopic or minimally invasive surgical necrosectomy
             and drainage.

        Exclusion Criteria:

          -  &lt;18 years old

          -  Unable to obtain informed consent from the patient or their medical representative.

          -  Medically unfit for general anesthesia

          -  Pregnant

          -  WOPN collection not accessible by either or both necrosectomy techniques.

          -  The collection has not matured and developed a wall, or is &gt;15mm from the lumen of
             the gastrointestinal tract.

          -  Irreversible coagulopathy: INR &gt;1.5

          -  Irreversible thrombocytopenia: platelet count &lt;50 x109/L, thrombocytopenia confirmed
             by manual count.

          -  Dual antiplatelet therapy or therapeutic anticoagulation that cannot be withheld for
             the procedure

          -  Surgical or endoscopic necrosectomy or pseudocyst drainage has been performed within
             the preceding 12 months

          -  WOPN secondary to trauma or other surgical event that requires additional
             interventions such as management of liver lacerations or vascular injury.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shyam S Varadarajulu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shyam S Varadarajulu, MD</last_name>
    <phone>407-303-2570</phone>
    <email>shyam.varadarajulu.md@flhosp.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy L Logue, RN, MSN</last_name>
    <phone>407-303-9736</phone>
    <email>amy.logue@flhosp.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Florida Hospital Center for Interventional Endoscopy</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>34786</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amy L Logue, RN, MSN</last_name>
      <phone>407-303-9736</phone>
      <email>amy.logue@flhosp.org</email>
    </contact>
    <contact_backup>
      <last_name>Shyam S Varadarajulu, MD</last_name>
      <phone>407-303-2570</phone>
      <email>shyam.vaaradarajulu.MD@flhosp.org</email>
    </contact_backup>
    <investigator>
      <last_name>Shyam S Varadarajulu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 10, 2014</lastchanged_date>
  <firstreceived_date>March 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>symptomatic</keyword>
  <keyword>infected</keyword>
  <keyword>necrotic collection</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
